Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5222486 | 0.86 | GSK3B (0.40) | — | |
| SCHEMBL11875236 | 0.86 | GSK3B (0.40) | — | |
| SCHEMBL505097 | 0.82 | HCAR1 (0.53) | CES2CES1 | |
| SCHEMBL2825638 | 0.81 | PARP1 (0.46) | CES2CES1 | |
| SCHEMBL1764880 | 0.81 | VNN1 (0.46) | — | |
| SCHEMBL20560236 | 0.81 | VNN1 (0.40) | — | |
| SCHEMBL10596241 | 0.81 | CES2 (0.45) | CES2CES1 | |
| Hydrochloric Acid SCHEMBL6524503 | 0.81 | HCAR1 (0.52) | CES2CES1 | |
| SCHEMBL2293145 | 0.79 | CES2 (0.55) | CES2CES1 | |
| SCHEMBL114867 | 0.79 | CES2 (0.62) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108698982-B | Fluorine atom-containing compound and use thereof | 日产化学工业株式会社 | 2021-07-16 | — | — | CN | disclosed |
| EP-3404017-B1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL IND LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10590287-B2 | Charge-transporting varnish and organic electroluminescent element | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2020-03-17 | — | — | US | disclosed |
| EP-3252840-B1 | VARNISH FOR FORMATION OF CHARGE-TRANSPORTING THIN FILM | NISSAN CHEMICAL CORP (JP) | 2020-03-11 | — | — | EP | disclosed |
| CN-107710440-B | Charge-transporting varnish and organic electroluminescent element | 日产化学工业株式会社 | 2019-12-24 | — | — | CN | disclosed |
| CN-106132923-B | Oligoaniline derivative, charge-transporting varnish and organic electroluminescent device | 日产化学工业株式会社 | 2019-11-15 | — | — | CN | disclosed |
| CN-107210377-B | Varnish for forming charge-transporting thin film | 日产化学工业株式会社 | 2019-07-05 | — | — | CN | disclosed |
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| US-10301484-B2 | Varnish for formation of charge-transporting thin film | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| CN-1649865-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| CN-1379775-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2002-11-13 | — | — | CN | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1210344-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012627-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | ARF1, ARF5, ARFGAP1 | CES2 2869/4885CES1 4049/4885 |
| US-10590287-B2 | Charge-transporting varnish and organic electroluminescent element | SLCO4C1, SLCO2A1, SLC26A3 | CES2 398/4885CES1 1582/4885 |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | CES2 1108/4885CES1 2945/4885 |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | ARF1, ARF5, ARFGAP1 | CES2 2869/4885CES1 4049/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | CES2 1108/4885CES1 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.